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ABSTRACT: MALDI imaging mass spectrometry (MALDI-IMS) has been
used successfully in mapping different lipids in tissue sections, yet existing
protocols fail to detect the diverse species of mitochondria-unique
cardiolipins (CLs) in the brain which are essential for cellular and
mitochondrial physiology. We have developed methods enabling the
imaging of individual CLs in brain tissue. This was achieved by eliminating
ion suppressive effects by (i) cross-linking carboxyl/amino containing
molecules on tissue with 1-ethyl-3-[3-(dimethylamino)propyl]-carbodiimide
hydrochloride and (ii) removing highly abundant phosphatidylcholine head
groups via phospholipase C treatment. These treatments allowed the
detection of CL species at 100 μm resolution and did not affect the amount or molecular species distribution of brain tissue CLs.
When combined with augmented matrix application, these modifications allowed the visualization and mapping of multiple CL
species in various regions of the brain including the thalamus, hippocampus, and cortex. Areas such as the dentate and stratum
radiatum exhibited higher CL signals than other areas within the hippocampal formation. The habenular nuclear (Hb)/dorsal
third ventricle (D3 V) and lateral ventricle (LV) areas were identified as CL “hot spots”. Our method also allowed structural MS/
MS fragmentation and mapping of CLs with identified fatty acid residues and demonstrated a nonrandom distribution of
individual oxidizable (polyunsaturated fatty acid containing) and nonoxidizable (nonpolyunsaturated containing) CLs in different
anatomical areas of the brain. To our knowledge, this method is the first label-free approach for molecular mapping of diversified
CLs in brain tissue.
In eukaryotes, the cardiolipins (CL), a class of mitochond-rion-specific anionic phospholipids, play multiple structural
and functional roles in bioenergetics, mitochondrial signaling,
and cellular fate pathways. While the aggregate abundance of
CLs in cells and tissues is low relative to other phospholipids
(2−3 mol %) within the mitochondrion, about a quarter of the
phospholipid molecules in the inner mitochondrial membrane
(IMM) is CLs, particularly in the matrix-oriented leaflet. CLs
are associated with multiple integral and peripheral mitochon-
drial proteins, from electron-transporting respirasomes to anion
channels and enzymes, and are present in a noncomplexed
form, thereby contributing to the extreme curvature of
mitochondrial cristae.1−5 During mitochondrial stress or
damage, the asymmetric CL distribution collapses resulting in
its externalization to the outer mitochondrial membrane
(OMM), leading to signaling events essential for mitophagy
and apoptosis.2,6,7 The general structure of CL (1,3-bis(sn-3′-
phosphatidyl)-sn-glycerol) is a unique dimeric moiety,
composed of two phosphatidylglycerols connected via a
glycerol backbone, which displays two negative charges from
the phosphate groups and four acyl chains. In polyunsaturated
CL species, these acyl chains readily undergo enzymatic
oxygenation2 which we have recently identified as a novel
generator of lipid mediators in mitochondria.8
This extraordinarily significant role in cell and mitochondrial
physiology leads to a pressing need to develop quantitative
methods to define the isoforms of CL, their dynamics,
expression, and of course distribution in tissues. Contemporary
liquid-chromatography/mass spectrometry (LC-MS) does
allow us to identify, characterize, and quantify individual
CLs.9,10 Unfortunately, no specific or reliable “labels”
(fluorescent probes, antibodies) or in fact methods to define
and localize the tissue distribution of brain CLs, in total and as
subtypes, exists. While variants of imaging mass spectrometry
(IMS) have been used to demonstrate the spatial distribution of
a number of abundant (phospho)lipids in tissue, there have
been no reports on the successful imaging of CLs in brain
tissue.11−13 This is because of the very low abundance of CLs
combined with their remarkable diversification and distribution
over numerous molecular species in the brain in contrast to
many other tissues.14
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Here, we report novel methods for the IMS of different CL
species in brain tissue sections which allows label-free spatial
resolution. Using this approach, we have (1) visualized and
mapped multiple CL species, (2) performed structural MS/MS
fragmentation and mapping of CLs with identified fatty acid
residues, and (3) demonstrated a nonrandom distribution of
individual polyunsaturated fatty acid (PUFA) containing and
non-PUFA containing CLs in different anatomical areas of the
brain.
■ EXPERIMENTAL SECTION
Reagents. Chloroform and ethanol (HPLC grade) were
purchased from Sigma-Aldrich (St. Louis, MO, USA).
Methanol was LC-MS grade from Fisher Scientific (Pittsburgh,
PA, USA). Water was purified by a Milli-Q system (EMD
Millipore, Billerica, MA, USA). 1-Ethyl-3-[3-(dimethylamino)-
propyl]carbodiimide hydrochloride (EDC) was purchased from
Thermo Scientific/Pierce Biotechnology (Rockford, IL, USA).
Phospholipase C (PLC) from B. cerus, ammonium acetate, and
2,5-dihydroxybenzoic acid (DHB) were also purchased from
Sigma-Aldrich (St. Louis, MO, USA).
Animals and Tissue Preparation. All procedures were
preapproved and performed according to the protocols
established by the Institutional Animal Care and Use
Committee of the University of Pittsburgh. Brains from 17
day old male Sprague−Dawley rats were harvested and
immediately frozen in liquid nitrogen with neither fixation
nor embedding and cut immediately. Brain tissue was affixed to
a cryotome block with minimal Tissue-Tek OCT (Sakura
FineTek USA, Torrance, CA, USA). The blade and working
surfaces of the cryotome were cleaned with methanol
immediately prior to cutting and at no time did the blade
come into contact with OCT. Coronal brain sections from
Bregma A 2.3 mm to A 3.2 mm were cut at −21 °C at a
thickness of 10 μm. These sections were applied to cold
histology slides coated with a conductive indium−tin oxide
(ITO) surface (Delta Technologies LTD, Loveland, CO, USA).
Additional sections were cut and applied to plain glass slides for
immunohistochemistry, hematoxylin and eosin (H&E) staining,
and total lipid extraction. Lipid extraction from dried tissue
sections on glass slides was performed using the modified Folch
method as described previously.15 Total lipid extracts were
dried under a steady stream of grade 5.0 N2, then redissolved in
2:1 chloroform/methanol to a total volume of 150 μL, and
stored at −80 °C prior to use.
In order to apply matrix more homogeneously than
airbrushes or TLC sprayers can achieve, we constructed a
capillary-sprayer from the electrospray source from a Thermo-
Finnigan TSQ 7000 mass spectrometer. The existing capillary
was replaced with 75 μm i.d. polyimide coated capillary tubing
(Scientific Instrument Services, Ringoes, NJ, USA). Sheath gas
(grade 5.0 N2) was regulated to 80 psi at the output of the
nitrogen regulator. Further fine control of nitrogen gas was
achieved using a needle valve to maintain a flow rate of 30 L/h.
The spray nozzle was placed at 35 mm above the tissue. A
syringe pump delivered matrix solution at a rate of 2.0 μL/min.
This combination of gas flow, height, and deposition rate gave
optimal coverage of the tissue sections. For CL imaging, the
tissue was first treated with 50 μL of 500 mM EDC (1-ethyl-3-
[3-(dimethylamino)propyl]carbodiimide) in MES buffer (100
mM, pH 3.7) for 2 h at room temperature and washed with 50
mM ammonium acetate buffer (200 μL, pH 6.7). The tissue
was then treated with PLC (0.01 units total in 50 μL of 50 mM
ammonium acetate buffer, pH 6.7) for 15 min at 37 °C
followed by an additional wash with ammonium acetate buffer
as described above. After the chemical/enzymatic treatments,
the tissue was vacuum-dried for 2 h and DHB matrix (480 mM
in chloroform/methanol, 2:1, v/v) was applied in 2 s bursts
with 120 s of drying time in between. This comprised one
spraying cycle. A total of 20 cycles was applied to the tissue.
Spraying in short (2 s) time increments with drying intervals (2
min) in-between each spray aided in controlling solvent effects.
A total of 12 brain sections from three different animals was
EDC/PLC treated, and matrix was applied to image lipids at
750, 200, 100, and 50 μm resolutions (see below).
Mass Spectrometry Analysis. MALDI-MS and -IMS
analyses were performed using Bruker Ultraflex II and
UltraFlextreme axial-TOF/TOF mass spectrometers and a
Solarix XR FTICR (Fourier transform ion cyclotron resonance)
mass spectrometer equipped with a 7.0 T magnet (Bruker
Daltonics, Billerica, MA, USA). The Ultraflex was equipped
with a 337 nm wavelength N2 laser operating at a repetition
rate of 20 Hz while the UltraFlextreme and Solarix were
equipped with 355 nm NdYAG lasers (1000 Hz repetition
rate). The MALDI-TOF MS spectra were acquired in reflector
mode with a matrix deflection cutoff of 400 Da in both positive
and negative polarities over a window of m/z 400−4000.
MALDI-FTICR-MS spectra were acquired in negative polarity
mode over a window of m/z 300−4000 with 8 megaword
transients and a data reduction coefficient of 0.98. MALDI-
TOF-MS/MS spectra were acquired in LIFT mode with
negative polarity and a mass isolation window of 0.8% of the
parent mass. This window size allowed full signal transmission
of ions from one CL cluster but gave no signal from adjacent
clusters. MALDI-TOF spectra were externally calibrated using a
phospholipid mixture while MALDI-FTICR spectra were
calibrated using a lock mass on the monoisotopic peak of
GM1 (d18:1/18:0, m/z 1544.86944, [M − H]−). MALDI-IMS
images from the Ultraflex were acquired at lateral resolutions of
either 200, 100, or 50 μm for IMS or 750 μm for MS/MS
imaging, with a summation of either 100 (positive mode), 800
(negative mode), or 3000 (MS/MS mode) laser shots per
location. MALDI-MS/MS images from the UltraFlextreme
were acquired at a lateral resolution of 200 μm with a
summation of 2000 laser shots per location. MALDI-FTICR-
MS images from the Solarix were acquired at a lateral resolution
of 100 μm with an ion accumulation of 300 laser shots per
location and one analysis step. Random walking was performed
every 10 (Ultraflex), 50 (Solarix), or 200 (Ultraflextreme) laser
shots within each location. Spectra from the Ultraflex were
acquired with a global attenuator offset of 60% and an
attenuator range of 20% of the maximum. Within that range, a
laser energy of 40% was used for positive mode and 50% for
negative and MS/MS-mode. Spectra from the Ultraflextreme
were acquired with a laser focus setting of 1 (minimum) and an
attenuator offset of 49% with a range of 51% of the maximum.
Within this range, a laser energy of 100% was used. Spectra
from the Solarix were acquired with a laser focus setting of 1
(minimum) and an attenuator offset of 0% with a range of
100%. Within this range, a laser energy of 23% was used.
MALDI-IMS images were produced from the corresponding
spectra which generated a heat map at a given m/z value using
FlexImaging 3.0 (Ultraflex) and FlexImaging 4.0 (Ultra-
Flextreme and Solarix) software (Bruker Daltonics, Billerica,
MA, USA). Heat maps for a given ion were generated with a
mass window of ±0.25 Da (TOF) or 0.001 Da (FTICR) and
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based on relative intensities with root-mean-squared (RMS)
normalization (FlexImaging 4.0) or no normalization (Flex-
Imaging 3.0) unless otherwise noted. Spectra from individual
imaged areas were analyzed with FlexAnalysis 3.0 (Ultraflex),
FlexAnalysis 3.3 (UltraFlextreme), and DataAnalysis 4.1
(Solarix). Spatial overlays of heat maps with histological
features were determined by coregistering fiducial markers on
optical images acquired from a microscope prior to matrix
deposition and consulting The Rat Brain in Stereotaxic
Coordinates.16
LC-MS/MS analyses (to confirm CL structure) were
performed on extracts of tissue slices17 on a Thermo Q-
Exactive hybrid quadrupole-orbitrap mass spectrometer (Ther-
moFisher, Inc., San Jose, CA). CLs were analyzed using a Luna
C8 column (2.0 mm (i.d.) × 15 cm, 5 μm, Phenomenex, Inc.)
on a Dionex Ultimate 3000 HPLC system (Thermo Fisher
Scientific, San Jose, CA). The column compartment was
maintained at 30 °C. Solvents consisted of 2-propanol/water/
triethylamine/acetic acid (45:5:0.25:0.25, isocratic). For CL
quantitation, LC was performed on a Luna Silica column (2.0
mm × 15 cm) using a hexane/propanol/water solvent system
(43:57:1, solvent A; 43:57:10, solvent B) containing 10 mM
ammonium acetate. Gradient: 10−37% B in 15 min; 37−65% B
in 8 min and 65−100% B in 2 min; hold at 100% B for 22 min.
Tetramyristoyl CL (TMCL) was used as an internal standard.
Flow was maintained at 0.2 mL/min. Analysis was performed in
negative ion mode at a resolution of 140,000 for the full MS
scan and 35,000 for the MS2 scan in a data-dependent mode.
The scan range for MS analysis was 1200−1600 m/z with a
maximum injection time of 100 ms using 1 microscan. A
maximum injection time of 128 ms was used for MS2 (high
energy collisional dissociation (HCD)) analysis with collision
energy set to 24. An isolation window of 1.0 and 0.5 Da was set
for the MS and MS2 scans, respectively. Capillary spray voltage
was set at 4.0 kV, and capillary temperature was 320 °C.
Immunohistochemistry and Fluorescent Imaging of
Mitochondria in Rat Brain Tissue Sections. Thin (10 μm)
frozen sections were cut, mounted on slides, labeled with
antibodies to TOM 20 (cat. # sc-11415/A3113, Santa Cruz
Biotechnology, Inc., Dallas, TX), nuclei counter stained with
Hoescht dye, and mounted as previously described.18 Entire
sections were scanned, and images were collected using a
Nikon 90i (Melvillen, NY, USA) upright microscope, 20× dry
plan apochromat objective, and motorized stage. Individual
images were stitched together using Nikon Elements software.
To overlay the MALDI-IMS data with the immunocytochem-
ical data, fiduciary structures common to the semiserial IMS
and light microscopy images were identified. The MALDI-IMS
images were resized such that the pixel count matched that of
the light microscopy images and images combined into a single
file. Various additive combinations of the MALDI-IMS images
were made and rendered to the same bit depth (12 bit) as the
light microscopy images and ratios calculated of MALDI-IMS
intensity/mitochondrial label intensity generated. These images
are displayed as pseudocolored images with a ratio between 0
and 2.
■ RESULTS AND DISCUSSION
Treatment with EDC and PLC Enables the Detection
of CL in Rat Brain Tissue. MALDI-IMS has been used to
define the localization of multiple classes of lipids in frozen
tissue sections, with the brain being the preferred tissue.19−29
Established conventional methods using 2,5-DHB as the matrix
provide precise lipid mapping and spectra (Supplementary
Figure 1a, Supporting Information) for multiple classes in the
negative ion mode including phosphatidylserines (PS),
phosphatidylinositols (PI), sulfatides (ST), and gangliosides
in the m/z range of 700−2,000. However, the m/z range of
1,400−1,600, in which CLs exist is predominately populated by
signals from ganglioside GM1 (Supplementary Figure 1a,
Supporting Information) and is devoid of signals from any CL
species (Figure 1a).
We reasoned that the inability to detect CLs was due in part
to the ion suppression of the limited CL signals by other more
abundant lipid ions such as phosphatidylcholine (PC) and
further by the highly abundant and easily ionized carboxyl and
amino groups of proteins and other lipids. Accordingly, we
Figure 1. MALDI-IMS and LC-MS spectra of untreated (a,c) and
EDC/PLC-treated (b,d) rat brain tissue. MALDI spectra in the CL
region, m/z 1420−1540, directly from untreated (a) and EDC-PLC
treated (b) tissue sections display a strong increase in signal for CL as
a result of EDC-PLC treatment. LC-MS of total lipid extracts from
untreated (c) and treated (d) tissue verify that the treatment does not
significantly affect the composition of tissue CL. A range of m/z
1420−1540 was chosen because the IMS spectrum (see Supplemental
Figure 1a, Supporting Information) was dominated by ganglioside
signals beyond m/z 1540. However, additional CL clusters were noted
in the region beyond m/z 1540 for the LC-MS spectrum.
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introduced two major modifications to conventional protocols:
(i) chemical cross-linking of the tissue surface with 1-ethyl-3-
[3-(dimethylamino)propyl]carbodiimide hydrochloride (EDC)
and (ii) treatment with phospholipase C (PLC). EDC cross-
links accessible carboxyl and amino groups on tissue and hence
limits ionization. PLC limits highly abundant/ionizable PC
signals by removal of cationic head groups. Although no gross
morphological changes were noted, it is possible that, when the
EDC and PLC treatments are utilized in tandem, they may
induce a complex reorganization of the tissue surface which aids
in CL detection by MALDI-IMS. Other major changes
included a modification of the matrix application methods by
construction of a spraying device that allowed for improved
control of the matrix deposition on tissue. We chose the matrix
2,5-DHB in combination with a chloroform/methanol solvent
system. This protocol allowed visualization and mapping of
multiple CLs in brain tissue (Figure 1b) centering around CL
clusters of m/z 1426 [(16:1)1/(18:2)1/(18:1)2], 1450
[(18:1)1/(18:2)3], 1476 [(18:1)2/(18:2)1/(20:4)1], 1500
[(18:1)2/(20:4)2; (18:0)1/(18:2)2/(22:6)1], and 1524
[(18:1)2/(20:4)1/(22:6)1], the same major CL clusters
detectable by LC-MS (Figure 1c). Near unit mass resolution
was achieved in the MALDI imaging spectra allowing the
mapping of various brain CLs. With a spatial resolution of 200
μm (Bruker Ultraflex II), a good compromise between heat
map and spectral quality was achieved. While imaging at higher
spatial resolutions (100 and 50 μm) was possible, it also
resulted in a significant decrease in CL signals (Supplementary
Figure 2, Supporting Information).
This approach afforded heat maps and spectra of brain CLs.
A comparison of CL spectra from treated and untreated tissue
indicated that there were no significant differences in CL
molecular species (Figure 1c,d) after EDC/PLC treatment. The
treated tissue displayed the same five clusters of CL as the
untreated tissue. When quantitative analysis was performed, the
amount of endogenous CL remained essentially unchanged
(3.3 ± 0.24 pmol/nmol Pi, untreated vs 3.1 ± 0.17 pmol/nmol
Pi, EDC/PLC treated) as determined by LC/MS in the
presence of TMCL (internal standard). Signals of other lipids
in the negative ion mode included sulfatides (STs),
phosphatidylinositols (PIs), and gangliosides GM1 and GD1
(Supplementary Figure 1a and Supplementary Table 1b,
Supporting Information). One exception was the isobaric
species at m/z 834.6 (phosphatidylserine (PS) and ST,
Supplementary Figure 1a, Supporting Information). Here, the
decreased signal was due to an inability of PS to ionize as a
result of the EDC coupling reaction. In positive mode imaging,
EDC/PLC-treated tissue displayed the same positive mass ions
as the untreated tissue albeit at a much lower signal intensity
(Supplementary Figure 3a,b,c and Supplementary Table 1a,
Supporting Information). Essentially, PC signals were de-
creased most significantly followed by PE, the latter due to
EDC cross-linking. However, each modification of the EDC/
PLC protocol was essential as omission of any treatment was
associated with a decrease or loss of CL signal.
Mapping the Spatial Distribution of CL Molecular
Species in Rat Brain Tissue. This innovative protocol
allowed the previously impossible comparison of the
distribution of 21 CL species within several CL clusters in
brain subregions (Figure 2a and Supplementary Figure 1b,
Supporting Information). Overall, higher intensities of CLs
mapped to centrally located areas, such as the dentate and
stratum radiatum, within the hippocampal formation. Higher
mass CL species (m/z 1476, 1496, 1500, and 1502) also
produced signals in the cortical region and while CLs were
present in the white matter their signals were much reduced.
Figure 2. Mapping the spatial distribution of CL species in rat brain. (a) Relative-intensity heat maps of select CL species (m/z 1426, 1452, 1470,
1474, and 1502) from EDC-PLC treated rat brain coronal sections (right hemisphere). An optical image and a heat map of ganglioside GM1 (m/z
1517) are included for comparison. Parentheses indicate CL fatty acyl chain carbon number and the number of double bonds, respectively. Scale bar
= 1 mm. Spatial resolution = 200 μm. (b) CL spectra were obtained from one individual pixel from each of the representative anatomical regions
(arrows, optical image) from rat brain. These include the medial dorsal thalamic nuclear (region A), the habenular nuclear (Hb) and dorsal 3rd
ventricle (D3 V) (region B), the retrosplenial cortex (region C), the dentate gyrus (DG) (region D), the external capsule white matter (region E),
and the CA2 regions (region F).
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This region-specific expression of different CL species was also
detectable at the single pixel (200 μm) level (Figure 2b) in
diverse anatomical regions, including the medial dorsal thalamic
nuclear (region A), the habenular nuclear (Hb) and dorsal third
Figure 3. FTICR MALDI IMS of CL species from rat brain. (a) Heat maps of 17 individual CL species from an EDC-PLC treated rat brain coronal
section (right hemisphere). An optical image is included for comparison. Parentheses indicate CL fatty acyl chain carbon number and the number of
double bonds, respectively. Scale bar = 1 mm. Spatial resolution = 100 μm. (b) Generated spectrum from the lateral ventricle (LV) area. (c)
Generated spectrum from the Hb/D3 V area. The associated high resolution mass spectra were generated from a single 100 μm pixel from the LV
and Hb/D3 V regions (arrows, optical and heat map image).
Figure 4. UltraFlextreme MALDI IMS analysis of fatty acyl fragments from the CL m/z 1448, 1476, and 1498 clusters. MS/MS analysis was
performed on the CL clusters centered around m/z 1448 (72:X), 1476 (74:X), and 1498 (76:X). An optical image and heat maps (bar = 1 mm) for
fragments of m/z 253, 255, 279, 281, 283, 303, 327, 329, and 331 are shown. Spatial resolution = 200 μm.
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ventricle (D3 V) (region B), the retrosplenial cortex (region
C), the dentate gyrus (DG, region D), the external capsule
white matter (region E), and the CA2 regions (region F).
Notably, the medial dorsal thalamic nuclear region yielded a
spectrum almost devoid of CL signal whereas the Hb/D3 V
region was a CL “hot spot” with a robust signal centered
around m/z 1474. We are certain that pixels without CL signals
were not due to absence of matrix as signals for other lipids
such as ST (m/z 806.5) and PI (m/z 885.5) were robust
(Supplementary Figure 4, region A, Supporting Information).
Spectra from the cortical, DG, and CA2 areas (region C, D, and
F, Figure 2b) exhibited four major CL clusters centered around
m/z 1450, 1474, 1500, and 1524. Regions A−F also exhibited
robust phospholipid signals with differences in intensities
relating to spatial locations (Supplementary Figure 4,
Supporting Information).
Continued refinement of the mapping of CLs by FTICR MS
(Solarix XR, FTICR, Bruker Daltonics, Billerica, MA)
permitted us to (i) obtain images of 17 CL species at 100
μm resolution and to map a larger area encompassing the
hippocampus and (ii) map masses for individual CL species to
a 0.001 Da mass accuracy (Figure 3a). With this increased
spatial resolution, four very low abundance CL species became
undetectable. The CL species of m/z 1425.980 and 1427.996
were robust in the hippocampal location with a decreased
density in the thalamus and cortex. CL species of m/z 1447.964
and 1449.980 had a similar distribution in the cortex,
hippocampal, and thalamic areas with lower intensities for
CLs of m/z 1451.996, 1454.011, and 1456.027. In addition, CL
species of m/z 1447.964 displayed an intense signal in the Hb/
D3 V area. Higher resolution imaging confirmed that the Hb/
D3 V region was a consistent “hot spot” for CL and identified
the lateral ventricle (LV) as an additional “hot spot” (see
arrows). Overall, the thalamic, hippocampal, and cortical areas
of the brain were enriched with asymmetrical (containing chiral
carbons) polyunsaturated species such as CLs of m/z 1475.996,
1497.980, and 1499.996 in addition to the symmetrical
tetralinoleoyl-CL (m/z 1447.964). CL spectra/images gener-
ated by FTICR were baseline resolved (Figure 3b,c; see also
higher resolution images for other lipid species in Supple-
mentary Figure 5, Supporting Information, and a complete
listing of all accurate masses in Supplementary Table 2,
Supporting Information).
MS/MS Analysis Maps CLs with Identified Fatty Acid
Residues to Rat Brain Regions. To provide identification of
CL species, we employed MS/MS analysis of CL clusters using
a Bruker UltraFlextreme mass spectrometer (Bruker Daltonics,
Billerica, MA) at 200 μm spatial resolution (Figure 4). An
increased parent isolation window was needed to generate
signals of sufficient intensity for fragmentation. Numerous fatty
Figure 5. Ratiometric analysis of CL-IMS intensity to mitochondrial immunofluorescence intensity. Rat brain coronal sections (right hemispheres)
were prepared for CL-IMS, and CL heat maps were generated. Semiserial brain sections were also prepared for mitochondrial immunohistochemical
(IHC) staining using a fluorescent-labeled TOM 20 antibody. Ratiometric images for individual or grouped CL species are presented. (a) MS image
intensities for 17 individual CL species were normalized to an 8 bit range and ratioed with the mitochondrial IHC image. Ratiometric images are
displayed as a heat map on a scale from 0 (purple, less CL relative to mitochondria) to 3 (red, more CL relative to mitochondria). (b) CL-IMS
groupings (panels 1−4) include: all CL species (All CL); CLs containing at least one PUFA of 18, 20, or 22 carbons (CL (72,74,76:X)); CLs
containing at least one PUFA of 20 or 22 carbons (CL (74,76:X)); non-PUFA containing CLs of m/z 1427.996 [(16:1)1/(18:1)3] and 1456.027
[(18:1)4]. These groupings are not normalized to the number of CL species; therefore, the absolute intensity will be highest in the heat map which
includes all CL species. Ratioed images of CL groupings (panels 5−8) were rendered to a 12 bit range and displayed as heat maps on a scale from 0
(purple, less CL relative to mitochondria) to 2 (red, more CL relative to mitochondria).
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acid fragments were detected including species with m/z 253
(C16:1), 255 (C16:0), 279 (C18:2), 281 (C18:1), 283
(C18:0), 303 (C20:4), 327 (C22:6), 329 (C22:5), and 331
(C22:4) within each CL cluster. The corresponding heat maps
(Figure 4) are presented on a relative intensity scale to aid in
displaying the spatial localization of very low abundance MS/
MS fragments. In addition, typical phosphatidic acid (PA)
fragments (a and b ions, m/z 695, 697, and 699) and lyso-PA
fragments (m/z 415, 417, and 419), normally seen upon CL
fragmentation, were evident (Supplementary Figures 6 and 7,
Supporting Information).30 The fragmentation analyses were in
agreement with the IMS acquisitions for the CL parent ions.
The linoleic acid fragment (m/z 279) from the 1476 cluster was
more abundant in the thalamic and cortical regions than in the
hippocampal formation (Figure 4). These results carried
through with the fragmentation of the m/z 1448 and 1498
clusters. The intensity of the m/z 279 fragment from the
various CL clusters was highest in the Hb/D3 V and LV areas
confirming these regions as CL “hot spots”. In addition, the
C22:5 (m/z 329) fragment from different CL clusters was
present at a higher level in the hippocampus, while the
arachidonic acid (C20:4, m/z 303) fragment was more
homogeneously distributed for all three CL clusters analyzed.
Images for intermediate CL fragments are presented in
Supplementary Figure 6, Supporting Information. The MS/
MS fragmentation pattern for the CL cluster m/z 1474 was also
confirmed on a lower resolution instrument (Bruker Ultraflex
II) with results shown in Supplementary Figures 7 and 8,
Supporting Information.
Ratiometric Analysis of CL/Mitochondria Displays
Different Distributions of PUFA vs Non-PUFA Contain-
ing CLs. With the logical assumption that the relative
distribution of individual CLs in mitochondria may vary
among anatomical areas of the brain, we performed ratiometric
analysis of CL images relative to mitochondrial abundance
using immunohistochemical (IHC) imaging of mitochondria
from semiserial sections (Figure 5a). Ratiometric data from the
individual CL species are presented in Supplementary Table 3,
Supporting Information. CL images were aggregated into 4
groupings: all CL, two PUFA groupings, and one non-PUFA
grouping; ratiometric images were generated (Figure 5b). In
general, IHC staining of mitochondria correlated very well with
our IMS data. Overall, a higher CL/mitochondria ratio was
found in the hippocampal area compared to the thalamus and
cortex for most of the individual CL species (Figure 5a and
Supplementary Table 3, Supporting Information). This was
also evident in the resulting intensities displayed in the
ratiometric image of all CL species (all CL, Figure 5b). Within
the hippocampal area, the pyramidal cell layer, DG and CA3
regions displayed a high density of CL while the white matter
region above the hippocampus displayed the lowest density of
CL relative to mitochondria (Figure 5a,b).
In the brain, the extraordinary geographic diversification of
CL may be associated with its two major functions: (i)
structural organization of electron transport chain complexes
and other mitochondrial membrane proteins and (ii) signal-
ing.3,5,8,31−33 It is believed that non-PUFA containing CL
species (with saturated and monounsaturated acyls) and
symmetric linoleoyl containing CL species mainly fulfill
structural requirements, whereas longer chain PUFA containing
CL species are used predominantly for signaling purpo-
ses.3,5,8,31−33 Ratiometric analysis revealed that the non-PUFA
containing CL species, m/z 1427.996 and 1456.027, mapped to
a more central hippocampal location with CL/mitochondria
ratios of 0.46 and 0.23, respectively (Figure 5a,b and
Supplementary Table 3, Supporting Information). These non-
PUFA containing CL species displayed extremely low
intensities in the thalamic nuclear and cortical regions (Figure
5a,b and Supplementary Table 3, Supporting Information) but
were present in the LV and Hb/D3 V areas. When the CLs
consisting of at least one PUFA chain containing 18, 20, or 22
carbons (CL 72:X, 74:X, and 76:X) were grouped and
ratiometric analysis was performed, much higher intensities
were noted in the thalamus and cortical regions (Figure 5b).
Similar ratiometric intensities for maps generated across the
thalamic, hippocampal, and cortical regions were evident for
CLs containing at least 20 or 22 carbon PUFA chains (Figure
5b). PUFA containing CL species also displayed a high CL/
mitochondria ratio in the Hb/D3 V and LV areas (Figure 5a,b
and Supplementary Table 3, Supporting Information). A
general trend was noted within each CL cluster; essentially
more saturated species also displayed a higher CL/mitochon-
drial ratio in the hippocampus relative to thalamus and cortex
as compared to the more unsaturated CL species (Supple-
mentary Table 3, Supporting Information). Overall, specific
abundance patterns of PUFA containing vs non-PUFA
containing CL species were revealed for different anatomical
regions of the brain.
IMS offers a unique opportunity for label-free analysis of
many types of individual phospholipids in tissue sections. The
remarkable analytical power of this methodology has been
successful for some lipid subclasses and in certain tissues where
mitochondria (and hence CL) are truly abundant. For example,
in cardiac tissue in which only a few CL isoforms predominate,
detection has been recently achieved.12,13 On the other hand in
the brain, in which CLs are present at low abundance and with
multiple isoforms, imaging has not been possible. Essentially,
this tissue remained an IMS “terra incognita.” Here, we show,
for the first time, a MALDI-IMS technique that allows the
imaging of important but low abundance CL species in different
anatomical regions of the brain. Our employment of modified
tissue protocols in conjunction with high mass accuracy FTICR
instrumentation and MS/MS fragmentation analysis allows
enhanced spatial resolution and identification of CL species in
this difficult tissue. Recently, an imaging mass spectrometry
study by Stutts et al. also utilized FTICR technology for the
mapping of oxidized phosphatidylcholine species in spinal cord
tissue.34 While we did not detect any oxidized cardiolipin
species from naiv̈e brain tissue sections, our method is directly
applicable to brain tissue sections from animals whose brain
function has been compromised, such as from traumatic brain
injury, an insult which has been shown to result in the
production of CL oxidation products.9
CLs regulate various enzymatic activities in mitochondria and
are essential components of dynamic supramolecular complexes
(respirasomes).31−33,35 Moreover, individual mitochondria may
display different bioenergetic-specific requirements for specific
CLs as described for murine brain tissue.36 In the brain, energy
usage is dictated by (a) region-specific metabolic demands, (b)
the response to a particular stimulus (signaling), and (c) the
developmental stage of the tissue.33 Accordingly, when all of
the CL species detected by IMS were integrated and ratiometric
analysis was performed, a clear correlation was found between
CL and a mitochondrial integral membrane protein TOM 20.
These data are in agreement with previous studies of other
mitochondrial markers like cytochrome oxidase (CO) in rat
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brain,37 whereby a low CO activity in the medial dorsal
thalamic nuclear region (our region A, Figure 2), a moderate
CO activity in the hippocampal formation (our region D,
Figure 2), and an unusually high degree of reactivity in the Hb
nuclear area (our CL “hot spot”, region B, Figure 2) were
detected.
The amazing spatial diversification of different CL isoforms
in the brain is numerically far greater than that seen in other
tissues.38 Moreover, the abundance of the long-chain PUFA
species in the brain cannot be explained exclusively by the
bioenergetic demands. Indeed, the diversity of CL isoforms in
the mitochondria of many highly effective ATP-generating
tissues is very limited, mostly limited to saturated and mono-
and diunsaturated fatty acid residues. It has been suggested, but
never experimentally proven, that tetra-, penta-, and hexaenoic
CL species fulfill other fundamental, signaling functions in the
brain.8,38 Our IMS data demonstrate, for the first time, the
heterogeneity of PUFA containing and non-PUFA containing
CLs in different anatomical areas of the brain. Combined with
our previously demonstrated role for PUFA-CLs as precursors
of lipid mediators,8 our data provides direct experimental
evidence for the concept of CL-dependent signaling via the
generation of lipid mediators. The CL species, which we have
mapped to the thalamic and hippocampal areas which contain
arachidonoyl and docosahexanoyl fatty acid chains (m/z
1473.977, 1475.991, 1478.010, 1495.963, 1497.979, and
1499.995), would inevitably serve as excellent substrates for
these types of signaling lipids. We have also defined the LV as
an additional CL “hot spot”, whereby the PUFA containing CL
species (m/z 1473.976 and 1475.991) may also serve as a
source of signaling lipid mediators. The latter region-specific
CL species from the choroid plexus (CP)/LV area contains one
or more 20:4 acyls which may serve as precursors to
thromboxanes (TXs), the major signaling lipid produced by
the CP.39 Many of the PUFA containing CL species we have
detected display a higher CL/mitochondrial ratio within the
hippocampal formation. Given the role of the hippocampus in
learning, memory, and spatial navigation, it is tempting to
speculate that these diversified PUFA-CLs are needed to fulfill
signaling roles essential for homeostatic and regulatory
functions involving cellular proliferation, differentiation, and
synaptogenesis.8,39−42
The ability to perform MS/MS analysis underlies the detailed
verification of region-specific fatty acyl compositions of CLs in
brain tissue as it relates to CLs as a source of lipid mediators.
We have shown that, when fragmented, many of the CL
clusters which contain C20:4, C22:5, and C22:6 acyls (m/z
303, 329, and 327, respectively) display a widespread though
specific distribution in the thalamic, hippocampal, and cortical
regions. These PUFA containing CL species are potentially
susceptible to attack by cyt c/H2O2 and release by PLA2
hydrolysis that can lead to a variety of lipid mediators in
these areas of the brain.8
■ CONCLUSIONS
In conclusion, we have been able to map individual CL
molecular species in brain tissue sections using our modified
tissue protocol and demonstrate, for the first time, the
heterogeneity of PUFA containing and non-PUFA containing
CLs in different anatomical regions of the brain. In addition, we
have defined the LV and Hb/D3 V areas of the brain as CL
“hot spots”. Finally, our modified protocol also allowed us to
map the fatty acyl profiles of several CL clusters to various brain
regions. Our novel method for the imaging of various CL
species and their fatty acyl compositions in the brain offers new
opportunities to obtain insights into a number of biologically
intriguing questions concerning the involvement of CL in
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